

Cover Story
Clinical
If you’ve been following the saga of drug shortages in this publication, you know how America’s cancer institutions are scrambling to obtain platinum-based drugs for their patients.
Capitol Hill
By Matthew Bin Han Ong
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”














